

Q-linea participates in tender for rapid AST

The region of Tuscany in Italy has announced a tender for rapid AST instruments and consumables which Q-linea will participate in. The tender is proof that the market for rapid AST is now taking off and growing.

“Our team of experts have been working closely with clinicians, lab managers and hospital administrators in Tuscany, and across Italy, to illustrate the value of rapid AST to patients and health systems. This tender is an example of that investment bearing fruit, and we expect to see more tenders across Europe as the body of evidence grows that rapid AST reduces the clinical burden of sepsis and reduces overall costs of managing the disease,” said Stuart Gander, President of Q-linea.

The tender has a validity of three plus two years and a total value of EUR 2,625,900. It involves nine sites across the region of Tuscany for a total of 3,500 tests per year. The tender is issued by ESTAR (Ente di supporto tecnico-amministrativo regionale), the regional administrative technical support body in Tuscany.

About ASTar Instrument and ASTar BC G- Kit

ASTar Instrument and ASTar BC G- Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.

ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea

Stuart.Gander@qlinea.com

+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB

Christer.Samuelsson@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar[®] is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

Q-linea participates in tender for rapid AST